Loading organizations...
§ Private Profile · Boston, MA, USA
Develops architected biomaterial scaffolds for tissue regeneration with AI 3D bioprinting for life sciences R&D.
Founded in 2021 by Filippos Tourlomousis, Boston-based Biological Lattice Industries develops architected biomaterial scaffolds for tissue regeneration using artificial intelligence-powered 3D bioprinting and laboratory automation. The startup provides life sciences and pharmaceutical researchers with its proprietary BioLoom multi-tool bioprinter and the Loominus Studio software platform to precisely design and fabricate advanced biomaterials. Operating as a business-to-business enterprise across the synthetic biology and regenerative medicine sectors, the company sells robotic biofabrication hardware and offers on-demand manufacturing services to R&D clients developing novel therapies and human enhancement devices. To support its ongoing commercialization efforts, the venture recently secured $1.8 million in pre-seed funding led by institutional investor Uni.Fund and its founding partner Katerina Pramatari. This early-stage financing builds upon initial proof-of-concept backing from the Massachusetts Institute of Technology's e14 Fund to further democratize complex laboratory biofabrication workflows.
Biological Lattice Industries has raised $1.8M across 1 funding round.
Biological Lattice Industries has raised $1.8M in total across 1 funding round.
Biological Lattice Industries has raised $1.8M across 1 funding round. Most recently, it raised $1.8M Pre-Seed in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 18, 2024 | $1.8M Pre Seed | Uni.fund | — | Announced |
Biological Lattice Industries has raised $1.8M in total across 1 funding round.
Biological Lattice Industries's investors include Uni.Fund.